Advertisement ยท 728 ร— 90

Posts by Samir Nusair MD ๐Ÿ‡ฎ๐Ÿ‡ฑ

Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD This is a PDF-only article. Please click on the PDF link above to read it.

Important statement on using GLI vs. GOLD spirometry criteria for the diagnosis of #COPD

publications.ersnet.org/content/erj/...

1 month ago 0 0 0 0
Preview
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025 Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. While ...

Excellent review on modern therapeutic options available for #scleroderma
rmdopen.bmj.com/content/11/3...

2 months ago 1 0 0 0
Post image

There are no Piranhas in Africa

2 months ago 0 0 0 0
Brian May plays Queen's '39' at the 2014 Starmus Festival
Brian May plays Queen's '39' at the 2014 Starmus Festival YouTube video by Astronomy magazine

Mixing science with music
'39

youtu.be/K9jvseJDN2k?...

4 months ago 1 0 0 0

The importance of bedside teaching of #Medicine
#MedicinePractice #MedicalEducation
www.nejm.org/doi/full/10....

4 months ago 0 0 0 0
Preview
What Drives Lung Cancer in Nonsmokers? Lung cancer among nonsmokers is associated with germline risk factors, and EGFR/ALK-targeted therapies provide substantial benefit, a review finds.

What Drives #LungCancer in Nonsmokers?
This is rapidly growing clinical problem

www.medscape.com/viewarticle/...

5 months ago 1 0 0 0
Preview
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjรถgren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjรถgren's d...

Sjogren disease therapy making nice progress since I reviewed pilocarpine for xerostomia in SS 25 years ago. Read "research in context" box.
www.thelancet.com/journals/lan...

5 months ago 1 0 0 0

Very interesting ๐Ÿ‘‡

6 months ago 0 0 0 0

small vessel vasculitis-necrosis?

6 months ago 0 0 0 0
Post image

Antifibrotic therapy does not alter the natural history of #pulmonaryhypertension in #pulmonaryfibrosis and other #progressivePF #fibroticILD

bmcpulmmed.biomedcentral.com/articles/10....

6 months ago 1 0 0 0
Advertisement
Preview
The prognostic importance of worsening dyspnoea in systemic sclerosis related interstitial lung disease To determine the prognostic importance of worsening dyspnoea in systemic sclerosis (SSc) related interstitial lung disease (ILD).SSc patients were recโ€ฆ

Dyspnea worsening is a strong predictor of ILD progression in #Scleroserma and unlinked to changes in pulmonary function test
www.sciencedirect.com/science/arti...

7 months ago 1 0 0 0
Preview
Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis - Japanese Journal of Radiology Purpose Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose...

FDG accumulation (or lack of uptake) within interstitial lesions does not predict acute exacerbation risk in lung cancer
#pulmonaryfibrosis
link.springer.com/article/10.1...

7 months ago 1 0 0 0

Inhaled Recombinant human GM-CSF given 48w shows clinically significant ,around 10% rise in DLCO, with some yet not statistically significant improvement in QOL or Exercise capacity in #alveolarproteinosis #raredisease

7 months ago 2 0 0 0
Video

Our dog is inspired in her sleep, dreaming and runnig while I listen to an old lecture from the late Prof. Brian Whipp
#ExercisePhysiology #ExerciseTesting
#ERSCongress 2007

8 months ago 0 0 0 0
Preview
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials.

Another therapeutic option for #pulmonaryfibrosis is coming up: Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist for IPF and PPF
journal.chestnet.org/article/S001...

8 months ago 1 0 0 0
Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement BackgroundThe 2013 American Thoracic Society/European Respiratory Society Statement on the classification of the idiopathic interstitial pneumonias described 6 major and 2 rare subtypes of idiopathic interstitial pneumonia, as well as recognising unclassifiable disease.ObjectiveThe objective of this statement is to update the 2013 classification of interstitial pneumonia.MethodsFive co-chairs identified a committee of 32 experts in the field as well as two individuals with lived experience. Creation of the document was supported by a series of video meetings, first including the full committee and then subgroups assigned to draft specific sections of the document. The classification scheme was developed by consensus.ResultsThe multidisciplinary committee of experts identified four major advances to the classification of interstitial pneumonia: (1) expansion beyond idiopathic interstitial pneumonias to also include secondary causes; (2) identification of new subcategories and updated terms, including addition of bronchiolocentric interstitial pneumonia as a major pattern as well as changing from acute interstitial pneumonia to idiopathic diffuse alveolar damage and desquamative interstitial pneumonia to alveolar macrophage pneumonia; (3) subclassification of interstitial and alveolar filling disorders, with interstitial disorders further subclassified as fibrotic versus non-fibrotic; and (4) consideration of diagnostic confidence in patient evaluation and management. The committee also provided a comprehensive update on the status of potential molecular tools and identified future research priorities.ConclusionsThis update builds upon the previous classification approach by describing major advances in the classification of interstitial pneumonia over the last decade.

All is good. Would reclassification help us to adjust optimal treatment and improve outcomes and clinical decisions? I sure hope so.
publications.ersnet.org/content/erj/...

8 months ago 0 0 0 0
Preview
Calcium Supplementation, Genetic Susceptibility, and Idiopathic Pulmonary Fibrosis Risk: A Prospective Study The association between calcium supplementation and the risk of incident idiopathic pulmonary fibrosis (IPF) is largely unknown.This study aimed to inโ€ฆ

Intriguing findings suggest that #Calcium Supplementation and even more together with Genetic Susceptibility may increase the incidence of Idiopathic #PulmonaryFibrosis.
A prospective cohort study.
www.sciencedirect.com/science/arti...

8 months ago 0 0 0 0
Advertisement

Seems my point is well taken. Injury, enforces abstaining from exercise or modifications that compromise benefit on mitochondria.

9 months ago 2 0 0 0

I presume there is a J-curve in which heavy repeated load may have eventually a toll on the integrity and function of joints and supporting soft tissue.

9 months ago 1 0 1 0

How come with increased wisdom and knowledge in this age there is more idiocy?

9 months ago 5 0 2 0
Preview
A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss - Nature Metabolism In this study, the authors describe SANA, a nitroalkene derivative of salicylate, as a potential activator of creatine-dependent energy expenditure and thermogenesis in adipose tissue. Preclinical and...

A new approach to achieve weight loss, by increasing thermogenesis and promoting metabolism
www.nature.com/articles/s42...

9 months ago 0 0 0 0

the effect on 'later life' is valid if you maintain a life long training pattern

9 months ago 0 0 1 0

On the Cover of @annalsats.bsky.social a picture of the pediatric department from which the senior author of this paper comes. The building was savagely attacked by an Iranian missile On June the 19th.

10 months ago 0 0 0 0
Post image

Dupilumab and #lymphoma risk among patients with #asthma: a population-based cohort study #BiologicsAsthma
Increased incidence of T and NK cell lymphoma and CTCL.
Clinical implications, yet to be determined.
publications.ersnet.org/content/erj/...

10 months ago 0 0 0 0
Preview
ืคื’ื™ืขืช ื”ื˜ื™ืœ ื”ืื™ืจืื ื™ ื‘ืžื›ื•ืŸ ื•ื™ืฆืžืŸ: "ื™ืฉ ืžืขื‘ื“ื•ืช ืฉืื™ื‘ื“ื• ื”ื›ื•ืœ" ื”ื˜ื™ืœ ื”ืื™ืจืื ื™ ืฉืคื’ืข ื”ืฉื‘ื•ืข ื‘ืžื›ื•ืŸ ื•ื™ืฆืžืŸ ืœืžื“ืข ืฉื‘ืจื—ื•ื‘ื•ืช ื’ืจื ื ื–ืง ื›ื‘ื“ ื•ื”ื•ืชื™ืจ ืœื ืžืขื˜ ืœื‘ื‘ื•ืช ืฉื‘ื•ืจื™ื ืฉืœ ืžื™ื˜ื‘ ื”ืžื•ื—ื•ืช ื”ืžื“ืขื™ื™ื ื‘ื™ืฉืจืืœ. ืžืชื•ืš ื”ืฉื‘ืจ ื”ื ื•ืจื ื ื•ืœื“ื” ืžื—ื•ื™ื‘ื•ืช ืœืฉื™ืงื•ื ื”ืžื—ืงืจ. ืคืจื•ืค' ืืœื“ื“ ืฆื—ื•ืจ, ื—ื•ืงืจ ืžื—ืœื•ืช ืœื‘: "ื”ืžืข...

On the devastating damage the researchers at Weizmann institute sustained from an Iranian missle

www.ynet.co.il/health/artic...

10 months ago 0 0 0 0
Preview
Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease <p>Dr. Mohleen Kang chats with Dr. Kerri Johannson and Dr. Tamera Corte about their article, "<a rel="nofollow"href="https://www.ats...

An @atscommunity.bsky.social podcast on environmental factors contributing to interstitial lung disease #pulmonaryfibrosis #fibroticILD
castbox.fm/app/castbox/...

10 months ago 1 0 0 0
Advertisement
Post image

Rentosertib, A generative AI-discovered TNIK inhibitor for idiopathic #pulmonaryfibrosis: a randomized phase 2a trial
Interesting if consistently confirmed effective, seems to have a relatively small rate of GI side effects.
www.nature.com/articles/s41...

10 months ago 1 0 0 0

So banal and so understanable.

11 months ago 1 0 0 0
Post image

Remarkable: a treatment for progressive pulm. fibrosis #fibroticILD. #Nerandomilast a molecule with #antifibrotic and anti-inflammatory effect, slows down FVC deterioration. Additionally, a weak signal of benefit on secondary end points, seen beyond week 52 of therapy.
www.nejm.org/doi/full/10....

11 months ago 0 0 0 0
Post image

Nerandomilast slows FVC deterioration in IPF patients without/with background #antifibrotic therapy.
- No additional protection from IPF exacerbation
- Pirfenidone decreases plasma levels of Nerandomilast by 50% as opposed to nintedanib.
#pulmonaryfibrosis #ATS2025
www.nejm.org/doi/full/10....

11 months ago 1 0 0 0